vs
PRECIGEN, INC.（PGEN）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
PRECIGEN, INC.自由现金流更多（$-15.9M vs $-139.5M）
Precigen是一家美国生物技术企业，由Helen Sabzevari担任总裁兼首席执行官，专注于生物技术领域的相关研发与业务布局，在行业内拥有自身的技术积累与发展优势。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
PGEN vs RVMD — 直观对比
营收规模更大
PGEN
是对方的Infinity倍
$0
自由现金流更多
PGEN
多$123.6M
$-139.5M
损益表 — Q2 FY2023 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $1.8M | $0 |
| 净利润 | $-20.3M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | -1153.6% | — |
| 净利率 | -1149.9% | — |
| 营收同比 | -39.3% | — |
| 净利润同比 | -15.2% | -20.4% |
| 每股收益（稀释后） | $-0.08 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PGENRVMD
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | $1.8M | $3.8M | ||
| Q1 23 | $1.9M | $7.0M | ||
| Q4 22 | $1.8M | $15.3M |
净利润PGENRVMD
| Q4 24 | — | $-194.6M | ||
| Q3 24 | — | $-156.3M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-116.0M | ||
| Q3 23 | — | $-108.4M | ||
| Q2 23 | $-20.3M | $-98.3M | ||
| Q1 23 | $-22.7M | $-68.1M | ||
| Q4 22 | — | $-56.5M |
营业利润率PGENRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -1153.6% | -2845.1% | ||
| Q1 23 | -1231.2% | -1071.5% | ||
| Q4 22 | — | -402.5% |
净利率PGENRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -1149.9% | -2570.6% | ||
| Q1 23 | -1228.2% | -970.9% | ||
| Q4 22 | — | -368.6% |
每股收益（稀释后）PGENRVMD
| Q4 24 | — | $-1.13 | ||
| Q3 24 | — | $-0.94 | ||
| Q2 24 | — | $-0.81 | ||
| Q1 24 | — | $-0.70 | ||
| Q3 23 | — | $-0.99 | ||
| Q2 23 | $-0.08 | $-0.92 | ||
| Q1 23 | $-0.10 | $-0.72 | ||
| Q4 22 | — | $-0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $88.4M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $166.2M | $2.3B |
| 总资产 | $207.5M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PGENRVMD
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.7B | ||
| Q3 23 | — | $813.2M | ||
| Q2 23 | $88.4M | $909.5M | ||
| Q1 23 | $104.1M | $909.8M | ||
| Q4 22 | $56.0M | $644.9M |
总债务PGENRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | $43.2M | — |
股东权益PGENRVMD
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.7B | ||
| Q3 23 | — | $837.5M | ||
| Q2 23 | $166.2M | $930.8M | ||
| Q1 23 | $184.1M | $952.2M | ||
| Q4 22 | $126.3M | $685.2M |
总资产PGENRVMD
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $1.9B | ||
| Q3 23 | — | $984.2M | ||
| Q2 23 | $207.5M | $1.1B | ||
| Q1 23 | $241.5M | $1.1B | ||
| Q4 22 | $216.0M | $811.9M |
负债/权益比PGENRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $-15.9M | $-139.5M |
| 自由现金流率自由现金流/营收 | -898.1% | — |
| 资本支出强度资本支出/营收 | 5.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-129.8M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流PGENRVMD
| Q4 24 | — | $-138.3M | ||
| Q3 24 | — | $-130.4M | ||
| Q2 24 | — | $-128.2M | ||
| Q1 24 | — | $-160.6M | ||
| Q3 23 | — | $-100.5M | ||
| Q2 23 | $-15.8M | $-67.1M | ||
| Q1 23 | $-18.4M | $-62.4M | ||
| Q4 22 | $-65.0M | $-61.8M |
自由现金流PGENRVMD
| Q4 24 | — | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | — | $-130.6M | ||
| Q1 24 | — | $-163.7M | ||
| Q3 23 | — | $-103.0M | ||
| Q2 23 | $-15.9M | $-68.2M | ||
| Q1 23 | $-18.5M | $-64.1M | ||
| Q4 22 | $-70.0M | $-64.7M |
自由现金流率PGENRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -898.1% | -1784.5% | ||
| Q1 23 | -1001.7% | -914.6% | ||
| Q4 22 | -3968.7% | -421.8% |
资本支出强度PGENRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 5.7% | 29.3% | ||
| Q1 23 | 8.3% | 25.1% | ||
| Q4 22 | 279.3% | 18.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
